We qualified an assay for measuring serum caspase 3/7 levels from clinical samples and found that circulating caspase 3/7 increased in a statistically significant manner in CRC and sarcoma patients treated with dulanermin. This evidence concerns the gene CASP3 and colorectal carcinoma.